NeoGenomics Debuts PanTracer Family of Genomic Profiling Tests at ASCO 2025

NeoGenomics Launches c-MET CDx Assay to Guide Treatment Decisions for Advanced Non-Small Cell Lung Cancer

NeoGenomics to Participate in Upcoming June Investor Conferences

  • NeoLINK Login
  • Investors
Search
LogoNeoLINK Login
Menu
  • Home
  • Providers
    Providers
    • Oncology solutions
      • Lung cancer
      • Breast cancer
      • Colorectal cancer
      • Gastric cancer
      • Hematologic cancers
    • Pathology solutions
      • Test search
      • Lab services
    • Client support & resources
      • Certifications & licenses
      • Test requisition forms
  • Partners
    Partners
    • Biopharma services
    • Oncology data solutions
    • Regulatory support
  • Patients
  • About NeoGenomics
    About NeoGenomics
    • Who we are
    • Scientific contributions
    • Careers
    • Privacy
    • Contact us
  • Billing
    Billing
    • For clinicians
    • For patients
    • Financial assistance
    • Pay your bill online
  • Test Search
  • Investors
Test Search
Skip to main content Skip to section navigation Skip to footer
NeoGenomics, Inc. IR Overview
  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Presentations
    • Literature
    • Email Alerts
  • Company Info
    • Overview
    • Executive Team
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Info
    • Quote
    • Chart
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • ESG
    • Report

Press Releases

Investors News & Events Press Releases
Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Presentations
    • Literature
    • Email Alerts
  • Company Info
    • Overview
    • Executive Team
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Info
    • Quote
    • Chart
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • ESG
    • Report
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Presentations
  • Literature
  • Email Alerts
Apr 25, 2013 7:00 am EDT
NeoGenomics Reports Record Quarterly Revenue of $15.7 Million, Adjusted EBITDA of $1.8 Million and 46.3% Gross Margin for the First Quarter
Apr 17, 2013 3:00 pm EDT
NeoGenomics Schedules its Q1 2013 Earnings Release for April 25, 2013
Feb 28, 2013 7:00 am EST
NeoGenomics Announces Pricing of $9.5 Million Public Offering
Feb 14, 2013 7:00 am EST
NeoGenomics Reports 181% Increase in Adjusted EBITDA on 38% Revenue Growth and Achieves Profitability in 2012
Feb 5, 2013 2:25 pm EST
NeoGenomics Schedules its Q4 and Full Year 2012 Earnings Release for February 14, 2013
Dec 17, 2012 7:00 am EST
NeoGenomics Validates and Launches NeoSITEā„¢ Barrett's Esophagus FISH Test for Surveillance and Diagnosis of High Grade Dysplasia/Esophageal Cancer
  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 21
  • Page 22
  • Page 23
  • Page 24
  • Page 25
  • Page 26
  • Page 27
  • Page 28
  • Page 29
  • Page 30
rss_feed News RSS
  • emailEmail Alerts
  • location_cityCompany Profile
  • rss_feedRSS News Feed
  • account_treeSitemap
©2025 NeoGenomics, Inc. All Rights Reserved.
  • Privacy Policy
  • Disclaimer
  • Sitemap
  • Accessibility Statement
  • Manage Cookie Preferences